A Single-center, Randomized, Double-blinded and Placebo-controlled Clinical Study in Healthy Chinese Subjects to Evaluate the Pharmacokinetics, Safety and Tolerability of LXI-15028 After Receiving Escalating Single Oral Doses of LXI-15028 at 50 mg, 100 mg and 200 mg and Multiple Oral Doses of LXI-15028 at 100 mg
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2018
At a glance
- Drugs Tegoprazan (Primary)
- Indications Erosive oesophagitis; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Shandong Luoxin Pharmaceutical
- 28 May 2018 Status changed from recruiting to completed.
- 26 Mar 2018 Status changed from not yet recruiting to recruiting.
- 14 Mar 2018 New trial record